氟羟强的松龙治疗活动性系统性红斑狼疮。

Frentizole therapy of active systemic lupus erythematosus.

作者信息

Kay D R, Valentine T V, Walker S E, Valentine M H, Bole G G

出版信息

Arthritis Rheum. 1980 Dec;23(12):1381-7. doi: 10.1002/art.1780231209.

Abstract

Frentizole is a benzimidazoleurea that has immunosuppressive properties in mice. Eleven steroid-treated patients with active systemic lupus erythematosus received frentizole (150-350 mg/day) in combination with stable or decreasing doses of prednisone in an open label trial. Nine patients completed at least one 21- to 75-day course of therapy with this drug. Clinical parameters of disease improved in 8 of these 9 patients. Mean DNA binding decreased by 28%, mean CH50 increased by 20%, and mean absolute lymphocyte and T cell counts decreased by 25-26%. Granulocytopenia was not observed. Three patients developed reversible hepatic toxicity. Clinical and serologic improvement was noted in 3 patients who accepted a second 90-day course of frentizole therapy.

摘要

氟仑替唑是一种苯并咪唑脲，在小鼠中具有免疫抑制特性。在一项开放标签试验中，11名接受类固醇治疗的活动性系统性红斑狼疮患者接受了氟仑替唑（150 - 350毫克/天），并联合使用稳定或递减剂量的泼尼松。9名患者完成了至少一个为期21至75天的该药物治疗疗程。这9名患者中有8名患者的疾病临床参数得到改善。平均DNA结合率下降了28%，平均总补体活性增加了20%，平均绝对淋巴细胞和T细胞计数下降了25 - 26%。未观察到粒细胞减少。3名患者出现可逆性肝毒性。3名接受第二个90天氟仑替唑治疗疗程的患者出现了临床和血清学改善。